Onze-Lieve-Vrouwziekenhuis

The department is testing innovative approaches for congestive heart failure and non‑ischemic cardiomyopathy, while also exploring therapies for hypertrophic cardiomyopathy and resistant hypertension.

• Advanced heart failure therapies
• Gene‑based treatment for non‑ischemic cardiomyopathy
• Renal denervation in uncontrolled hypertension
• Sotagliflozin for symptomatic hypertrophic cardiomyopathy
• Management of ATTR amyloidosis with cardiomyopathy

At Onze‑Lieve‑Vrouwziekenhuis, patients benefit from a multidisciplinary heart team that integrates cutting‑edge research with clinical care.

A broad portfolio of studies targets advanced solid tumors, including breast, ovarian, prostate, lung, and urothelial cancers, focusing on targeted and immunotherapy combinations.

• Triple‑negative breast cancer immunotherapy
• FGFR‑directed agents for urothelial carcinoma
• Hormone‑based strategies for metastatic prostate cancer
• KRAS‑G12C inhibitors combined with checkpoint blockade in NSCLC
• High‑grade serous ovarian cancer with folate‑receptor targeting

The oncology programme at the site leverages state‑of‑the‑art imaging and molecular profiling to personalize treatment.

Researchers are evaluating novel inhaled and systemic agents for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, aiming to preserve lung function.

• Inhaled treprostinil for progressive lung disease
• AXATILIMAB safety and efficacy in IPF
• Anti‑fibrotic compounds targeting FVC decline
• Combination therapy with immunomodulators in fibrotic lung disease
• Long‑term safety monitoring of inhaled treatments

Patients receive comprehensive pulmonary assessment alongside trial participation.

The site conducts trials on weight management, blood pressure control, and cardiovascular risk reduction in type 2 diabetes and obesity.

• Tirzepatide versus dulaglutide for major cardiovascular events
• Finerenone plus empagliflozin for renal protection
• RO7795068 for weight reduction in overweight adults
• Baxdrostat dose‑finding study for resistant hypertension
• Metabolic outcomes in obese patients without diabetes

Collaborative care with endocrinology ensures integrated management of metabolic disorders.

Multiple studies focus on moderate to severe Crohn’s disease and ulcerative colitis, testing new induction agents and postoperative recurrence strategies.

• AZD7798 for ulcerative colitis induction
• Therapeutic escalation after ileocolonic anastomosis in Crohn’s disease
• Biomarker‑driven treatment de‑escalation in IBD
• Long‑term remission maintenance with novel biologics
• Comparative efficacy of oral versus intravenous IBD therapies

The gastroenterology unit provides endoscopic and imaging support for trial participants.

Trials address serious infections such as invasive candidiasis and severe community‑acquired pneumonia, comparing new antifungal regimens and immune‑modulating proteins.

• IV echinocandin followed by oral ibrexafungerp for candidemia
• Trimodulin evaluation in severe pneumonia mortality
• Antimicrobial stewardship interventions in hospital settings
• Safety assessment of next‑generation antifungals
• Outcomes in resistant bacterial infections

Infection control specialists monitor safety and efficacy throughout the studies.

The department investigates immune‑modulating strategies for rheumatoid arthritis and other autoimmune conditions, emphasizing early remission and biomarker guidance.

• Accelerated anti‑TNF access for early rheumatoid arthritis remission
• Subcutaneous infliximab dosing frequency optimization
• Relacorilant combined with chemotherapy in gynecologic cancers
• Immune checkpoint blockade in advanced lung cancer
• Biomarker‑driven treatment de‑escalation in metastatic hormone‑sensitive prostate cancer

Immunology experts at the hospital integrate trial data with personalized patient care.